Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer. 2018

Qiang Du, and Ruofei Yu, and Han Wang, and Dong Yan, and Qi Yuan, and Yixin Ma, and Dennis Slamon, and Dongmei Hou, and Huiling Wang, and Qi Wang
Department of Respiratory Medicine, The Second Affiliated Hospital, Dalian Medical University, Dalian, China.

OBJECTIVE Autoantibodies tumor-associated antigens (TAAs) could be a valuable tool for the diagnosis or early detection of cancer due to their relatively high specificity and stability. The purpose of this study is to detect the level of tumor-associated autoantibodies in lung cancer and assess the diagnostic potential of autoantibodies in screening strategy for early stage lung cancer. METHODS Levels of tumor-associated autoantibodies (AAbs) were measured against a panel of seven TAAs (p53, PGP9.5, SOX2, GAGE7, GBU4-5, CAGE and MAGEA1) in 397 patients with pulmonary lesions (305 with newly diagnosis of NSCLC, 47 with SCLC and 45 with benign nodule) and 74 control persons without any nodules in the lung after chest MDCT scan. The sensitivity, specificity for patients and control persons, positive rate of the panel in different pathology, stage, size of lesion, age and gender were compared and analyzed. RESULTS The AAbs panel could distinguish malignant lesions from benign lesions and control people, with sensitivity of 56.53% and specificity of 91.60%. The specificity could be further increased to 95.80%, when combined with CT. The AAbs also showed high diagnostic value of malignant nodule, and it would be a new method for judgment of malignant nodules that are less than 8 mm in diameter. No significant differences were seen based on pathology, NSCLC stages, tumor size, age or gender. CONCLUSIONS This assay confirms the value of AAbs panel as a diagnostic tool combined with CT scan.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D012372 ROC Curve A graphic means for assessing the ability of a screening test to discriminate between healthy and diseased persons; may also be used in other studies, e.g., distinguishing stimuli responses as to a faint stimuli or nonstimuli. ROC Analysis,Receiver Operating Characteristic,Analysis, ROC,Analyses, ROC,Characteristic, Receiver Operating,Characteristics, Receiver Operating,Curve, ROC,Curves, ROC,ROC Analyses,ROC Curves,Receiver Operating Characteristics
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Qiang Du, and Ruofei Yu, and Han Wang, and Dong Yan, and Qi Yuan, and Yixin Ma, and Dennis Slamon, and Dongmei Hou, and Huiling Wang, and Qi Wang
January 2021, Advances in clinical chemistry,
Qiang Du, and Ruofei Yu, and Han Wang, and Dong Yan, and Qi Yuan, and Yixin Ma, and Dennis Slamon, and Dongmei Hou, and Huiling Wang, and Qi Wang
December 2021, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine],
Qiang Du, and Ruofei Yu, and Han Wang, and Dong Yan, and Qi Yuan, and Yixin Ma, and Dennis Slamon, and Dongmei Hou, and Huiling Wang, and Qi Wang
September 2016, Lung cancer (Amsterdam, Netherlands),
Qiang Du, and Ruofei Yu, and Han Wang, and Dong Yan, and Qi Yuan, and Yixin Ma, and Dennis Slamon, and Dongmei Hou, and Huiling Wang, and Qi Wang
January 2020, Immunobiology,
Qiang Du, and Ruofei Yu, and Han Wang, and Dong Yan, and Qi Yuan, and Yixin Ma, and Dennis Slamon, and Dongmei Hou, and Huiling Wang, and Qi Wang
July 2012, Biochemical and biophysical research communications,
Qiang Du, and Ruofei Yu, and Han Wang, and Dong Yan, and Qi Yuan, and Yixin Ma, and Dennis Slamon, and Dongmei Hou, and Huiling Wang, and Qi Wang
January 2019, OncoTargets and therapy,
Qiang Du, and Ruofei Yu, and Han Wang, and Dong Yan, and Qi Yuan, and Yixin Ma, and Dennis Slamon, and Dongmei Hou, and Huiling Wang, and Qi Wang
May 2024, BMC pulmonary medicine,
Qiang Du, and Ruofei Yu, and Han Wang, and Dong Yan, and Qi Yuan, and Yixin Ma, and Dennis Slamon, and Dongmei Hou, and Huiling Wang, and Qi Wang
March 2011, Molecular cancer,
Qiang Du, and Ruofei Yu, and Han Wang, and Dong Yan, and Qi Yuan, and Yixin Ma, and Dennis Slamon, and Dongmei Hou, and Huiling Wang, and Qi Wang
June 2002, Zhongguo fei ai za zhi = Chinese journal of lung cancer,
Qiang Du, and Ruofei Yu, and Han Wang, and Dong Yan, and Qi Yuan, and Yixin Ma, and Dennis Slamon, and Dongmei Hou, and Huiling Wang, and Qi Wang
May 2017, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition,
Copied contents to your clipboard!